Bone density in myasthenia gravis patients receiving long-term prednisolone therapy

被引：16

作者：

Wakata, N ^{[1
]}

Nemoto, H ^{[1
]}

Sugimoto, H ^{[1
]}

Nomoto, N ^{[1
]}

Konno, S ^{[1
]}

Hayashi, N ^{[1
]}

Araki, Y ^{[1
]}

Nakazato, A ^{[1
]}

机构：

[1] Toho Univ, Sch Med, Dept Internal Med 4, Meguro Ku, Tokyo 1538151, Japan

来源：

CLINICAL NEUROLOGY AND NEUROSURGERY | 2004年 / 106卷 / 02期

关键词：

osteoporosis; bone density; deoxypyridinoline; DX method; CXD method; myasthenia gravis;

D O I：

10.1016/j.clineuro.2003.12.001

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Osteoporosis is an adverse effect of prednisolone therapy, although no study has been conducted on myasthenia gravis patients receiving high-dose prednisolone. We measured bone density in 36 patients (26 females and 10 males) who had undergone long-term prednisolone administration, and found a decrease in bone density in 31% of female patients and osteoporosis in only 11.5% (three cases). This frequency is lower than the presumptive rate of the general population in Japan (22.6%). No osteoporosis was detected in male patients. In conclusion, prednisolone-treated patients with myasthenia gravis have an acceptable risk of bone loss if prophylactic medication is administered. (C) 2004 Elsevier B.V. All rights reserved.

引用

页码：139 / 141

页数：3

共 11 条

[1]

INOUE T, 1983, Journal of the Japanese Orthopaedic Association, V57, P1923

[2] RATIONALE OF ALTERNATE-DAY CORTICOSTEROID THERAPY [J].

JACOBSON, ME .

POSTGRADUATE MEDICINE, 1971, 49 (02) :181-&

[3] Osteoporosis prevention in myasthenia gravis: a reminder [J].

Lewis, SJG ;

Smith, PEM .

ACTA NEUROLOGICA SCANDINAVICA, 2001, 103 (05) :320-322

[4] Osteoporosis in neurological disorders [J].

Lloyd, ME ;

Spector, TD ;

Howard, R .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (05) :543-547

[5]

LLOYD ME, 1998, J NEUROL NEUROSUR PS, V64, P702

[6] METACARPAL BONE MASS IN NORMAL AND OSTEOPOROTIC JAPANESE WOMEN USING COMPUTED X-RAY DENSITOMETRY [J].

MATSUMOTO, C ;

KUSHIDA, K ;

YAMAZAKI, K ;

IMOSE, K ;

INOUE, T .

CALCIFIED TISSUE INTERNATIONAL, 1994, 55 (05) :324-329

[7]

*NAT OST SOC, 1999, NAT OST SOC GUIDANCE

[8]

ORIMO H, 2002, OSTEOPOR JPN, V10, P7

[9]

Orimo H, 1996, OSTEOPOROSIS JAPAN, V4, P643

[10] Myasthenia gravis, corticosteroids and osteoporosis prophylaxis [J].

Smith, GDP ;

Stevens, DL ;

Fuller, GN .

JOURNAL OF NEUROLOGY, 2001, 248 (02) :151-151

← 1 2 →